Compare Novartis AG (NVS) vs BIO-TECHNE Corp (TECH) Price & Performance

Novartis AGTrade

BIO-TECHNE CorpTrade

Price performance (Past 24H)

Key statistics

Novartis AG vs BIO-TECHNE Corp — how do they compare? Novartis AG trades at $149.81 (market cap $290.25B), while BIO-TECHNE Corp trades at $71.63 (market cap $11.16B). The key difference: Novartis AG is far larger — about 26× BIO-TECHNE Corp's market cap, and Novartis AG pays the higher dividend (3.17%). Which is the better fit depends on your goals.

	NVS	TECH
Market Cap	$290.25B	$11.16B
Sector	Health	Health
52-Week High	$168.62	$72.12
52-Week Low	$113.50	$43.31
Enterprise Value	$330.27B	$11.24B
Dividend Yield	3.17%	0.45%

View details →View details →

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

NVS

Novartis Q2 earnings expected at $2.17 EPS, $14.07B revenue amid patent loss impact and key drug trials ahead.Gordon Thompson · 22 hours agoNeutral New report details 1,230+ bioinformatics deals, revealing market trends and deal structures through 2026Researchandmarkets.Com · 4 days agoNeutral FDA approves Fabhalta as first drug to significantly slow kidney decline in IgAN patientsNovartis · 4 days agoBullish View details →

TECH

View details →

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

About BIO-TECHNE Corp

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.